TSH 수용체 항체 측정의 임상적 의미 = Clinical Implication of TSH Receptor Antibody Measurement

다국어 초록 (Multilingual Abstract)

Autoantibodies directed against the thyrotropin receptor have been well known to be an important pathogenesis of Graves’ disease. However, the diagnosis and management of Graves’ disease are still mainly dependent on thyroid function itself and clinical manifestation of thyrotoxic patients. That is mainly due to the low sensitivity of early generation of thyrotropin receptor assay methods. The development of sensitive thyrotropin receptor measuring tools through third generation immunometric assay made the diagnosis of Graves’ disease with mild hyperthyroidism accurate and convenient for patients. Bioassay to detect thyroid stimulating immunoglobulin is also commercially available nowadays, which theoretically discriminate thyroid stimulating antibodies from thyrotropin receptor-blocking antibodies. Although the use of these serologic markers plays an informative role in accurately diagnosing Graves’ disease and predicting the prognosis of disease, consideration of the heterogeneous nature of autoimmunity of Graves’ disease and the limitation of indirect antibody assay is also required for proper management of Graves’ disease patients. In this review, the clinical usefulness of thyrotropin receptor antibody in various clinical situations of Graves’ disease was overviewed.

참고문헌 (Reference)

1 Tozzoli R, "TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis" 12 (12): 107-113, 2012

2 Michalek K, "TSH receptor autoantibodies" 9 (9): 113-116, 2009

3 Kamijo K, "Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease" 21 (21): 1295-1299, 2011

4 Carella C, "Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period" 16 (16): 295-302, 2006

5 Costagliola S, "Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease" 84 (84): 90-97, 1999

6 Morshed SA, "Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades" 151 (151): 5537-5549, 2010

7 Mukuta T, "Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSHbinding inhibitor immunoglobulin" 40 (40): 215-219, 1994

8 Bahn Chair RS, "Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists" 21 (21): 593-646, 2011

9 Hwang S, "High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months" 48 (48): 89-95, 2015

10 Stagnaro-Green A, "Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum" 21 (21): 1081-1125, 2011

11 Torring O, "Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group" 81 (81): 2986-2993, 1996

12 Vos XG, "Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study" 69 (69): 311-317, 2008

13 Zimmerman D, "Fetal and neonatal hyperthyroidism" 9 (9): 727-733, 1999

14 Paunkovic J, "Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis" 38 (38): 53-56, 2006

15 장선영, "Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves’ Orbitopathy" 연세대학교의과대학 54 (54): 1033-1039, 2013

16 Eckstein A, "Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy" 7 (7): 198-203, 2010

17 Zophel K, "Clinical review about TRAb assay's history" 9 (9): 695-700, 2010

18 Ponto KA, "Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy" 118 (118): 2279-2285, 2011

19 Jang SY, "Clinical characteristics of Graves' orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay" 80 (80): 591-597, 2014

20 Lytton SD, "Bioassays for TSH-receptor autoantibodies: an update" 10 (10): 116-122, 2010

21 Giuliani C, "A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment" 97 (97): E1080-E1087, 2012